Linked Life Data

9618071

Source:http://linkedlifedata.com/resource/pubmed/id/9618071

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9618071rdf:typepubmed:Citationlld:pubmed
pubmed-article:9618071lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:9618071lifeskim:mentionsumls-concept:C0014792lld:lifeskim
pubmed-article:9618071lifeskim:mentionsumls-concept:C0022655lld:lifeskim
pubmed-article:9618071lifeskim:mentionsumls-concept:C0022664lld:lifeskim
pubmed-article:9618071lifeskim:mentionsumls-concept:C0036394lld:lifeskim
pubmed-article:9618071lifeskim:mentionsumls-concept:C0027788lld:lifeskim
pubmed-article:9618071lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:9618071lifeskim:mentionsumls-concept:C0439830lld:lifeskim
pubmed-article:9618071lifeskim:mentionsumls-concept:C1148926lld:lifeskim
pubmed-article:9618071lifeskim:mentionsumls-concept:C0076808lld:lifeskim
pubmed-article:9618071lifeskim:mentionsumls-concept:C2348243lld:lifeskim
pubmed-article:9618071lifeskim:mentionsumls-concept:C0071629lld:lifeskim
pubmed-article:9618071pubmed:issue3lld:pubmed
pubmed-article:9618071pubmed:dateCreated1998-7-28lld:pubmed
pubmed-article:9618071pubmed:abstractTextLong-term prospective studies comparing the effects of conventional and intensive insulin therapy have linked diabetic hyperglycemia to the development of diabetic retinopathy, nephropathy, and neuropathy. The mechanisms through which glucose metabolism leads to the development of these secondary complications, however, are incompletely understood. In animal models of diabetic neuropathy, the loss of nerve function in myelinated nerve fibers has been related to a series of biochemical changes. Nerve glucose, which is in equilibrium with plasma glucose levels, rapidly increases during diabetic hyperglycemia because glucose entry is independent of insulin. This excess glucose is metabolized in large part by the polyol pathway. Increased flux through this pathway is accompanied by the depletion of myo-inositol, a loss of Na/K ATPase activity and the accumulation of sodium. Supportive evidence linking these biochemical changes to the loss of nerve function has come from studies in which aldose reductase inhibitors block polyol pathway activity, prevent the depletion of myo-inositol and the accumulation of sodium and preserve Na/K ATPase activity, as well as nerve function. The kidney and red blood cells (RBCs) are two additional sites of diabetic lesions that have been reported to develop biochemical changes similar to those in the nerve. We observed that polyol levels in the kidney cortex, medulla, and RBCs increased two- to ninefold in rats following 10 weeks of untreated diabetes. Polyol accumulation was accompanied by a 30% decrease in myo-inositol levels in the kidney cortex, but no change in RBCs or the kidney medulla. Na/K ATPase activity was decreased by 59% in RBCs but was unaffected in the kidney cortex or medulla. Aldose reductase inhibitor treatment that preserved myo-inositol levels, Na/K ATPase, and conduction velocity in the sciatic nerve also preserved Na/K ATPase activity in RBCs. Our results suggest that the pathophysiologic mechanisms underlying diabetic neuropathy are different from those of diabetic nephropathy. Our results also suggest that RBCs maybe a surrogate tissue for the assessment of diabetes-induced changes in nerve Na/K ATPase activity.lld:pubmed
pubmed-article:9618071pubmed:languageenglld:pubmed
pubmed-article:9618071pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9618071pubmed:citationSubsetIMlld:pubmed
pubmed-article:9618071pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9618071pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9618071pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9618071pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9618071pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9618071pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9618071pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9618071pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9618071pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9618071pubmed:statusMEDLINElld:pubmed
pubmed-article:9618071pubmed:issn1056-8727lld:pubmed
pubmed-article:9618071pubmed:authorpubmed-author:VaguePPlld:pubmed
pubmed-article:9618071pubmed:authorpubmed-author:CosteTTlld:pubmed
pubmed-article:9618071pubmed:authorpubmed-author:CameronN ENElld:pubmed
pubmed-article:9618071pubmed:authorpubmed-author:RaccahDDlld:pubmed
pubmed-article:9618071pubmed:authorpubmed-author:HohmanT CTClld:pubmed
pubmed-article:9618071pubmed:authorpubmed-author:DufayetDDlld:pubmed
pubmed-article:9618071pubmed:issnTypePrintlld:pubmed
pubmed-article:9618071pubmed:volume12lld:pubmed
pubmed-article:9618071pubmed:ownerNLMlld:pubmed
pubmed-article:9618071pubmed:authorsCompleteYlld:pubmed
pubmed-article:9618071pubmed:pagination154-62lld:pubmed
pubmed-article:9618071pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:9618071pubmed:meshHeadingpubmed-meshheading:9618071-...lld:pubmed
pubmed-article:9618071pubmed:meshHeadingpubmed-meshheading:9618071-...lld:pubmed
pubmed-article:9618071pubmed:meshHeadingpubmed-meshheading:9618071-...lld:pubmed
pubmed-article:9618071pubmed:meshHeadingpubmed-meshheading:9618071-...lld:pubmed
pubmed-article:9618071pubmed:meshHeadingpubmed-meshheading:9618071-...lld:pubmed
pubmed-article:9618071pubmed:meshHeadingpubmed-meshheading:9618071-...lld:pubmed
pubmed-article:9618071pubmed:meshHeadingpubmed-meshheading:9618071-...lld:pubmed
pubmed-article:9618071pubmed:meshHeadingpubmed-meshheading:9618071-...lld:pubmed
pubmed-article:9618071pubmed:meshHeadingpubmed-meshheading:9618071-...lld:pubmed
pubmed-article:9618071pubmed:meshHeadingpubmed-meshheading:9618071-...lld:pubmed
pubmed-article:9618071pubmed:meshHeadingpubmed-meshheading:9618071-...lld:pubmed
pubmed-article:9618071pubmed:meshHeadingpubmed-meshheading:9618071-...lld:pubmed
pubmed-article:9618071pubmed:meshHeadingpubmed-meshheading:9618071-...lld:pubmed
pubmed-article:9618071pubmed:meshHeadingpubmed-meshheading:9618071-...lld:pubmed
pubmed-article:9618071pubmed:meshHeadingpubmed-meshheading:9618071-...lld:pubmed
pubmed-article:9618071pubmed:meshHeadingpubmed-meshheading:9618071-...lld:pubmed
pubmed-article:9618071pubmed:meshHeadingpubmed-meshheading:9618071-...lld:pubmed
pubmed-article:9618071pubmed:meshHeadingpubmed-meshheading:9618071-...lld:pubmed
pubmed-article:9618071pubmed:meshHeadingpubmed-meshheading:9618071-...lld:pubmed
pubmed-article:9618071pubmed:meshHeadingpubmed-meshheading:9618071-...lld:pubmed
pubmed-article:9618071pubmed:articleTitleEffect of the aldose reductase inhibitor tolrestat on nerve conduction velocity, Na/K ATPase activity, and polyols in red blood cells, sciatic nerve, kidney cortex, and kidney medulla of diabetic rats.lld:pubmed
pubmed-article:9618071pubmed:affiliationLaboratory of Diabetology, University Timone Hospital, Marseille, France.lld:pubmed
pubmed-article:9618071pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9618071lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9618071lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9618071lld:pubmed